指南移除阿托品与成人院内非可除颤心律心脏骤停生存率的关系
该研究利用Get With The Guidelines®-复苏注册数据,纳入2006至2015年间成人院内指数心脏骤停患者,包括20499例非可除颤心律和3968例可除颤心律心脏骤停。采用中断时间序列分析比较2010年指南发布前后生存率变化,并用双重差分法比较非可除颤与可除颤队列,以排除与阿托品无关的指南变更影响。主要终点为出院生存率。结果显示,非可除颤队列与可除颤队列相比,指南前后生存率随时间变化的风险差为每年2.0%(95%CI:-0.8,4.8),P=0.17;指南引入后即刻生存率变化的风险差为3.5%(95%CI:-2.6,9.7),P=0.26,均无统计学显著差异。次要结局和多项敏感性分析结果相似。结论认为,2010年指南移除阿托品与生存率无显著变化相关。
要点
- 在20499例非可除颤心律和3968例可除颤心律院内心脏骤停中,指南前后生存率随时间变化的风险差为每年2.0%(95%CI:-0.8,4.8),P=0.17,无显著差异。
- 指南引入后即刻生存率变化的风险差为3.5%(95%CI:-2.6,9.7),P=0.26,非可除颤与可除颤队列间无显著差异。
- 阿托品使用率在指南前非可除颤心律为87%(8653例),指南后降至35%(3643例);可除颤心律由35%(680例)降至16%(320例)。
- 次要结局(自主循环恢复和良好功能结局)及多项敏感性分析结果与主要终点相似。
适用人群与场景
- 纳入2006至2015年间成人院内指数心脏骤停患者,包括非可除颤心律20499例和可除颤心律3968例。
研究设计与关键结果
- 研究类型为基于Get With The Guidelines®-复苏注册的注册研究,纳入20499例非可除颤心律和3968例可除颤心律成人院内心脏骤停患者。
- 主要终点为出院生存率;采用中断时间序列分析比较指南前后生存率变化,并用双重差分法比较非可除颤与可除颤队列。
- 非可除颤队列与可除颤队列相比,指南前后生存率随时间变化的风险差为每年2.0%(95%CI:-0.8,4.8),P=0.17。
- 指南引入后即刻生存率变化的风险差为3.5%(95%CI:-2.6,9.7),P=0.26。
- 阿托品使用率:指南前非可除颤心律87%(8653例),指南后35%(3643例);指南前可除颤心律35%(680例),指南后16%(320例)。
- 次要结局(自主循环恢复和良好功能结局)及多项敏感性分析结果与主要终点相似。
证据类型、等级与局限
- 证据类型:基于Get With The Guidelines®-复苏注册的注册研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: To determine whether the removal of atropine from the 2010 ACLS guidelines for non-shockable cardiac arrests was associated with a change in survival.
METHODS: Using the Get With The Guidelines®-Resuscitation registry, we included adults with an index in-hospital cardiac arrest between 2006 and 2015. The primary outcome was survival to hospital discharge. Secondary outcomes included return of spontaneous circulation and favorable functional outcome. An interrupted time-series analysis was used to compare survival before (pre-guidelines) and after (post-guidelines) introduction of the 2010 guidelines. A difference-in-difference approach was used to compare the interrupted time-series results between the non-shockable and shockable cohorts to account for guideline changes unrelated to atropine.
RESULTS: We included 20,499 non-shockable and 3968 shockable cardiac arrests. Patient characteristics were similar between the pre-guidelines and post-guidelines period. Atropine was used for 8653 (87%) non-shockable and 680 (35%) shockable cardiac arrests in the pre-guidelines period and 3643 (35%) non-shockable and 320 (16%) shockable cardiac arrests in the post-guidelines period. The change over time in survival from the pre-guidelines to the post-guidelines period was not significantly different for the non-shockable compared to the shockable cohort (risk difference: 2.0% [95%CI: -0.8, 4.8] per year, p = 0.17). The immediate change in survival after introducing the guidelines was also not different between the cohorts (risk difference: 3.5% [95%CI: -2.6, 9.7], p = 0.26). Results were similar for the secondary outcomes and in multiple sensitivity analyses.
CONCLUSIONS: The removal of atropine from the 2010 guidelines was not associated with a significant change in survival.
参考来源
- Holmberg MJ, Moskowitz A, Wiberg S, et al. Guideline removal of atropine and survival after adult in-hospital cardiac arrest with a non-shockable rhythm. Resuscitation. 2019. PMID: 30771452. doi:10.1016/j.resuscitation.2019.02.002
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。